Hatteras Venture Partners has secured over $200 million across a pair of funds that are set to benefit up-and-coming biotechs ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting ...

Generation Bio is shedding 90% of its workforce after the biotech acknowledged that it’s unlikely to find the cash to take ...

Using its hub-and-spoke business model, PureTech is launching a new company to develop deupirfenidone (LYT-100), its ...

After the Department of Health and Human Services canceled about $500 million in funding for mR | After HHS abruptly canceled ...

The director of the National Institutes of Health (NIH) has said the federal government’s discontinuation of mRNA vaccine ...

The company said its CGM+ system can deliver accurate readings across a 15-day lifespan, while also employing fewer ...

More bad news has come down for Biohaven’s small molecule troriluzole. | More bad news has come down for Biohaven’s small molecule troriluzole. After the FDA decided to convene an advisory committee ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Vaxart is actively seeking more information about why it was told to stop work under a federally funded COVID-19 vaccine ...

Activist investor Engine Capital is lobbying for big changes at Avantor, urging the life science toolmaker to either cut costs and reshape its management or sell itself outright. | The move comes as ...